Ocular Therapeutix (OCUL) Receivables - Net (2016 - 2026)
Ocular Therapeutix has reported Receivables - Net over the past 14 years, most recently at $24.3 million for Q1 2026.
- For Q1 2026, Receivables - Net fell 3.47% year-over-year to $24.3 million; the TTM value through Mar 2026 reached $24.3 million, down 3.47%, while the annual FY2025 figure was $30.6 million, 5.37% down from the prior year.
- Receivables - Net for Q1 2026 was $24.3 million at Ocular Therapeutix, down from $30.6 million in the prior quarter.
- Over five years, Receivables - Net peaked at $32.4 million in Q4 2024 and troughed at $19.8 million in Q3 2022.
- A 5-year average of $26.1 million and a median of $26.2 million in 2023 define the central range for Receivables - Net.
- Biggest five-year swings in Receivables - Net: surged 70.25% in 2022 and later decreased 8.98% in 2023.
- Year by year, Receivables - Net stood at $21.3 million in 2022, then rose by 22.76% to $26.2 million in 2023, then rose by 23.72% to $32.4 million in 2024, then decreased by 5.37% to $30.6 million in 2025, then decreased by 20.56% to $24.3 million in 2026.
- Business Quant data shows Receivables - Net for OCUL at $24.3 million in Q1 2026, $30.6 million in Q4 2025, and $30.8 million in Q3 2025.